DISCLAIMER: This news article is a direct translation of the original Korean article from Getnews. BioNote Inc. does not claim any right to the article or claim any ownership.

The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.
 

BioNotes (CEO Cho Byung-ki), a global leading bio-content and animal diagnosis company, recently launched overseas, announced on the 2nd that its cutting-edge field molecular diagnostic equipment Vcheck M10 (hereinafter M10) received favorable reviews for its technology at the 2022 World Small Animal Society (WSAVA) Congress.

The event was held in Lima, Peru from the 29th to the 31st of last month, and received high attention from veterinarians and veterinary diagnostic industry officials around the world for its M10 product's innovative technology, according to BioNote.

M10 is an automated device that integrates nucleic acid extraction and nucleic acid amplification (PCR) into one device, which was previously carried out by separate equipments. The M10 has a very simple inspection process, so using this equipment, veterinarians at general veterinary hospitals can conduct PCR tests at animal hospitals without additional training. This is groundbreaking because the PCR confirmation test, which was requested by a professional inspection agency, which took about 1 to 3 days, can be carried out quickly and accurately at field in an hour.

M10 has completed the export license of the quarantine headquarters and the European CE certification, and is preparing for domestic use. As a cartridge used in M10 equipment, "Vcheck MEhrlichia/Anaplasma" was launched overseas for the first time in September this year, and "Vcheck M Babesia gibsoni/canis" was developed as the second item and is being prepared for overseas launch in November.

BioNote said, "We have confirmed the market's great demand for M10 through the Vcheck M launch show and 2022 WSAVA in Latin America," adding, "BioNote, which has previously shown expertise in immunodiagnosis, aims to become a global leading company that provides total solutions from initial screening tests to PCR confirmation tests."

Source : Getnews (http://www.getnews.co.kr) Article Link: https://www.getnews.co.kr/news/articleView.html?idxno=604367